SOD1 nanozyme with reduced toxicity and MPS accumulation

Jiang, Yuhang; Arounleut, Phonepasong; Rheiner, Steven; Bae, Younsoo; Kabanov, Alexander V.; Milligan, Carol; Manickam, Devika S.

doi:10.1016/j.jconrel.2016.02.038

Cited by 52 publications

(39 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[40] Briefly, 5 μg of BDNF was mixed with 0.5 mCi Na 125 I in a final volume of 45 μL sodium PB (0.25 M, pH 7.5). Five μL of freshly prepared 2 μg μL −1 chloramine-T solution in PB was then added to the mixture and incubated for 1 min at RT.…”

Section: Methodsmentioning

confidence: 99%

Nanoformulation of Brain‐Derived Neurotrophic Factor with Target Receptor‐Triggered‐Release in the Central Nervous System

Jiang

Fay

Poon

et al. 2017

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) is identified as a potent neuroprotective and neuroregenerative agent for many neurological diseases. Regrettably, its delivery to the brain is hampered by poor serum stability and rapid brain clearance. Here, a novel nanoformulation is reported composed of a bio-compatible polymer, poly(ethylene glycol)--poly(L-glutamic acid) (PEG-PLE), that hosts the BDNF molecule in a nanoscale complex, termed here Nano-BDNF. Upon simple mixture, Nano-BDNF spontaneously forms uniform spherical particles with a core-shell structure. Molecular dynamics simulations suggest that binding between BDNF and PEG-PLE is mediated through electrostatic coupling as well as transient hydrogen bonding. The formation of Nano-BDNF complex stabilizes BDNF and protects it from nonspecific binding with common proteins in the body fluid, while allowing it to associate with its receptors. Following intranasal administration, the nanoformulation improves BDNF delivery throughout the brain and displays a more preferable regional distribution pattern than the native protein. Furthermore, intranasally delivered Nano-BDNF results in superior neuroprotective effects in the mouse brain with lipopolysaccharides-induced inflammation, indicating promise for further evaluation of this agent for the therapy of neurologic diseases.

show abstract

Section: Methodsmentioning

confidence: 99%

Nanoformulation of Brain‐Derived Neurotrophic Factor with Target Receptor‐Triggered‐Release in the Central Nervous System

Jiang

Fay

Poon

et al. 2017

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the other hand, several promising antioxidant nanoparticles (NPs) have been developed in recent years, with the perspective capacity of suppressing ROS-induced damage following ischemic stroke. [20] Exemplary work by Kabanov and co-workers on superoxide dismustase 1 (SOD1) containing nanozymes has shown that they are able to significantly reduce infarct volumes in both mice [21] and rat [22] models of ischemic stroke. [19] They also showed in a rat model of ischemic stroke that MeNPs reduce brain superoxide levels and infarct volume.…”

Section: Introductionmentioning

confidence: 99%

Reactive Oxygen Species‐Responsive Nanoparticles for the Treatment of Ischemic Stroke

Rajkovic

Gourmel

d’Arcy

et al. 2019

Advanced Therapeutics

View full text Add to dashboard Cite

Ischemic stroke is a leading cause of death and long-term disability worldwide, yet availability of current treatments is limited. The downstream events resulting from cerebral ischemia lead to an imbalance in the production of harmful reactive oxygen species (ROS) over endogenous antioxidant mechanisms. Thus, treatments that can reduce this imbalance can limit the extent of injury resulting from ischemic stroke. In this work, the potential of novel ROS-scavenging PEGylated polymeric nanoparticles (NPs) composed of poly(propylene sulfide) (PPS) (PPS-NPs) for ischemic stroke therapy is evaluated in vitro and in a mouse model of stroke. In vitro results show that PPS-NPs display remarkable anti-oxidant and anti-inflammatory properties, whilst exhibiting negligible cytotoxicity. NPs administered intravenously rapidly accumulate in ischemic brain regions as visualized through fluorescence imaging, reduced infarct volume, blood-brain barrier damage, neuronal loss, and neuroinflammation as determined by immunohistochemistry, and improved recovery of neurological function as determined through behavioral analyses. Crucially, the data show that the therapeutic time window for administration of PPS-NPs extends up to 3 h, a clinically relevant time window for stroke. The findings provide new strong evidence that these NPs may be an effective antioxidant therapy for ischemic stroke.

show abstract

“…Evacuated tubes were used to collect venous blood samples and ethylenediaminetetraacetic acid dipotassium was used as an anticoagulant. All plasma samples were processed as previously described (22)(23)(24). The plasma samples were processed in a centrifuge at 3,000 x g for 10 min at 4˚C and separated into a RNase-free tube.…”

Section: Methodsmentioning

confidence: 99%

Microarray and bioinformatics analysis of circular RNAs expression profile in traumatic lung injury

Jiang

Zhu

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Acute lung injury (ALI) and respiratory distress syndrome are common, potentially lethal injuries that predominantly occur following chest trauma. Circular RNAs (circRNAs) are stable conserved non-coding RNAs that are widely expressed in different organs. To the best of our knowledge, no previous studies have shown whether circRNAs are involved in traumatic lung injury (TLI). The aim of the present study was to identify highly expressed circRNAs in plasma samples from patients with TLI and explore their potential functions in the pathogenesis of TLI. A high-throughput circRNA microarray was used to investigate the expression profile of circRNAs in plasma samples from five patients with TLI and paired control samples. Subsequently, a total of five abnormally expressed circRNAs were investigated using reverse transcription-quantitative PCR (RT-qPCR). A bioinformatics analysis was performed to predict a competitive endogenous RNA (ceRNA) network. In addition, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to identify the main biological processes and pathways. Finally, additional samples were tested to identify the expression profiles of the selected circRNAs. Among the 310 circRNAs that were highly expressed in the microarray analysis, 60 were upregulated and 250 were downregulated in patients with TLI. RT-qPCR results indicated that two downregulated circRNAs (circ_102927 and circ_100562) and one upregulated circRNA (circ_101523) matched the microarray results. The bioinformatics analysis constructed a targeting network based on the three validated circRNAs. GO and KEGG analyses identified the top ten enriched annotations. The expression of homo sapiens circular RNA 102927 (hsa_circRNA_102927) in the plasma of patients with TLI was 0.34-fold compared with the control group in expanded size validation. The results of the present study identified the differentially expressed circRNAs in the plasma of patients with TLI and provided evidence that highly expressed circRNAs involved in the ceRNA network may serve a role in the pathophysiology of TLI.

show abstract

SOD1 nanozyme with reduced toxicity and MPS accumulation

Cited by 52 publications

References 59 publications

Nanoformulation of Brain‐Derived Neurotrophic Factor with Target Receptor‐Triggered‐Release in the Central Nervous System

Nanoformulation of Brain‐Derived Neurotrophic Factor with Target Receptor‐Triggered‐Release in the Central Nervous System

Reactive Oxygen Species‐Responsive Nanoparticles for the Treatment of Ischemic Stroke

Microarray and bioinformatics analysis of circular RNAs expression profile in traumatic lung injury

Contact Info

Product

Resources

About